



PRELIMINARY PROGRAM

(as of May 8, 2025)



Developing RNA based approaches for the treatment of Pompe Disease and neurodegenerative conditions

Emanuele Buratti

Group Leader, Molecular Pathology Lab, **ICGEB**, Italy



Breast cancer transcriptomics at the bulk, single cell and spatial levels

Carlos Caldas

Honorary Consultant in Medical Oncology, **University of Cambridge**, UK



Utilizing Machine Learning to Unlock RNA Delivery

Yogev Debbi

Co-Founder & CEO, **Mana.bio**, IL



DELiveri: Massive throughput screens to identify conjugates that promote cell delivery of nucleic acid therapeutics

Yaniv Erlich

CEO and Co-founder, **Eleven Therapeutics**, IL



RNA-binding proteins in melanoma progression

Fátima Gebauer

President of the **RNA Society** and Principal Investigator, **Center for Genomic Regulation (CRG)**, Spain



AI-Driven Design: Unlocking Novel Mechanisms in RNA Therapeutics

Tamar Grossman

CEO, **La Jolla Labs**, USA



RNA Horizons 2025 Therapeutics Symposium

Unlocking the RNA's Potential in Medicine

October 29-31, 2025 | Palermo, Sicily, Italy



Nucleic Acid Therapeutic Unlabeled Reporter Assay (NATURA): A novel platform for high-throughput quantification of NATs' functional delivery and potency

Ernesto Guccione

Principal Investigator, The Guccione Lab, **Icahn School of Medicine at Mount Sinai**, USA



Targeting RNA processing to induce neoantigens in cancer cells

Rotem Karni

Principal Investigator

Hebrew University-Hadassah Medical School, Jerusalem, IL, and **University of Pennsylvania**, USA



Bispecific siRNA to Reduce Cardiometabolic Risk

Michael Khan

CEO, **Argonaute RNA**, UK



SpliSense – A transformative RNA (ASOs) based company for the treatment of Pulmonary diseases

Gili Hart

SpliSense, IL



SRSF1-regulated alternative splicing controls on oncogenic circuit in pancreatic cancer

Adrian Krainer

Cold Spring Harbor Laboratory, New York, USA



Dual-function oligonucleotide strategies for immunotherapy of acute myeloid leukemia

Marcin Kortylewski

Principal Investigator, **The Kortylewski Lab City of Hope**, USA



RNA Horizons 2025 Therapeutics Symposium

Unlocking the RNA's Potential in Medicine

October 29-31, 2025 | Palermo, Sicily, Italy



Exploiting the dark genome to target drug-tolerant cells and improve anticancer immune therapies

Eleonora Leucci

Principal Investigator – RNA Cancer Biology Lab, **KU Leuven**, Belgium



Rewriting the Message: RNA Splice Disruption Unmasks New Cancer Immunotherapy Targets

Michal Lotem

Head of The Hadassah Cancer Research Institute (HCRI),
Hadassah Hebrew University Medical Center, Jerusalem, IL



Targeting m6A-RNA Biology in FTO-Dependent Cancers

Amir Mor

CSO, **RNAble**, IL



Improved Delivery of RNAs for Extra-Hepatic Delivery

Ruben Postel

CSO & Scientific Founder, **Sapreme Technologies**, The Netherlands



Harnessing RNA-Driven Intelligence to Revolutionize Personalized Cancer Therapy

Aron Popovtzer

Director of the Sharett Institute of Oncology, **Hadassah Medical Center**,
Jerusalem, IL



Therapeutic approaches for HNRNPH2-Related Neurodevelopmental Disorder, an ultra-rare neurogenetic disorder

Christopher Ricupero

Assistant Professor, **Columbia University Irving Medical Center**, USA



Exploiting RNA translation control to fight cancer resistance

Caroline Robert

Head of Dermatology, **Gustave Roussy Institute**, France



RNA Horizons 2025 Therapeutics Symposium

Unlocking the RNA's Potential in Medicine

October 29-31, 2025 | Palermo, Sicily, Italy



Translation dysregulation in cancer as a source for targetable antigens

Yarden Samuels

Director, Moross Integrated Cancer Center, Samuels Lab,
Weizmann Institute of Science, IL



Modeling and modulating antitumor immunity with RNA nanoparticles in 3D-bioprinted tumoroids

Ronit Satchi-Fainaro

Director, Cancer Biology Research Center, and Director, TAU Kahn 3D
BioPrinting Initiative, **TAU, IL**



Splicing dysregulation: hallmark and therapeutic opportunity in cancer

Claudio Sette

Principal Investigator, **Catholic University of the Sacred Heart, School
of Medicine, Italy**



Pseudoexon activation as a therapeutic approach

Brage Storstein Andresen

Head of Research, Brage Storstein Andresen Lab, **University of Southern
Denmark**



Aberrantly spliced cancer proteoforms: if you can't beat them, eat them!

Andrei Thomas-Tikhonenko

Director of Experimental Pathology, **Children's Hospital of Philadelphia,
USA**



Targeting noncoding elements to boost haploinsufficient gene expression

Igor Ulitsky

Principal Investigator, Ulitsky Lab, **Weizmann Institute of Science, IL**



miRNA-based logic circuits encoded on self-amplifying RNA for highly specific cancer cell classification

Ron Weiss

Principal Investigator, The Weiss Lab, **Massachusetts Institute of Technology**, Boston, USA

For further information, please visit our website:

<https://rnahorizons.com/>